齐拉西酮与利培酮治疗精神分裂症对照研究

Comparative study of ziprasidone and risperidone in the treatment of schizophrenia

目的评价齐拉西酮治疗精神分裂症的疗效及其不良反应。方法将60例精神分裂症患者随机分为齐拉西酮组和利培酮组,每组30例,观察8周疗程。疗效指标包括阳性和阴性症状量表(PANSS)及临床总体印象量表(CGI),不良反应指标为不良反应症状量表(TESS)及有关实验室检查。结果治疗结束时,齐拉西酮组有效率为86.7%,利培酮组为90.0%,两组疗效相当;治疗结束时,两组PANSS评分较入组时均显著减低,两组差异未达到统计学显著程度,但齐拉西酮对阴性症状的改善优于维思通;齐拉西酮组很少引起锥体外系反应、体重增加、月经改变。结论齐拉西酮治疗精神分裂症有较好的疗效,尤其有助于阴性症状的改善,不良反应比利培酮更少。

Objective To explore the efficacy and side effects of ziprasidone for treating patients with schizophrenia Methods A total of 60 patients with schizophrenia were randomly divided into ziprasidone group （30 cases） and risperidone group（30 cases） for the treatment of 8 weeks. Indicators included Positive and Negative Symptom Scale （PANSS） and Clinical Global Impression scale（CGI） for efficacy,Treatment Emergent Symptom Scale（TESS） and the laboratory for side effects. Results The effective rates of ziprasidone group and risperidone group were 86.7% and 90.0% after 8 -week treatment,and there was no significant difference between two groups. At the end of treatment, PANSS scores of both groups signifi effect on negative weight gain, Extra cantly reduced, no significant difference was found between two groups, however, ziprasidone had better symptoms than risperidone. The patients treated Pyramidal Symptoms（EPS） and menses change with ziprasidone showed fewer side effects including than the patients with risperidone. Conclusion Ziprasidone is effective in the treatment of schizophrenia, specifically improving negative symptoms. Ziprasidone has fewer side effects compared with risperidone.